ADESA

Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for inflammatory and immune-related diseases. The company's lead asset, paridiprubart (EB05), is a monoclonal antibody targeting Toll-like receptor 4 (TLR4) currently in Phase 3 clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS). Edesa is also advancing EB01, a topical sPLA2 inhibitor for chronic allergic contact dermatitis, and EB06, an anti-CXCL10 antibody for vitiligo. The company's strategy centers on providing novel alternatives to steroids and JAK inhibitors for large, underserved patient populations.